Chemomab Therapeutics Ltd. Logo

Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):
US16385C1045 (+1 more)
LEI:
Country:
United States of America
Address:
KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden
NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy
NWRN
NEXGEL, INC. Logo
Develops and manufactures advanced hydrogels for healthcare, OTC, and consumer applications.
United States of America
NXGL
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden
NXTCL
NextCure, Inc. Logo
Clinical-stage biopharma developing novel immunomedicines for cancer and other diseases.
United States of America
NXTC
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea
354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea
138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan
4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan
4516
Nkarta, Inc. Logo
Developing off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
NKTX

Talk to a Data Expert

Have a question? We'll get back to you promptly.